Boston Scientific Corporation
BSX
株式のランク
#409
この企業概要は英語でのみ提供されています。
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
株価
$41.88
最終同期: 2026-10-30
時価総額
$60.69B
変化（1日）
-1.89%
変化（1年）
-58.42%
国
US
株式データ: Financial Modeling Prep·更新日: ·投資助言ではありません·計算方法
取引 Boston Scientific Corporation (BSX)
カテゴリー
Healthcare
Boston Scientific Corporation（BSX）のP/B比率
November 2026 時点のP/B比率 TTM: 2.44
Boston Scientific Corporation の最新の財務報告および株価によると、現在のP/B比率（TTM）は 2.44 です。2025 年末時点でのP/B比率は 5.83 でした。
Boston Scientific Corporation の P/B 比率の履歴（2000 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 2.44 | -58.16% |
| 2025 | 5.83 | -3.52% |
| 2024 | 6.04 | 38.59% |
| 2023 | 4.36 | 15.67% |
| 2022 | 3.77 | 3.62% |
| 2021 | 3.63 | 9.38% |
| 2020 | 3.32 | -26.72% |
| 2019 | 4.53 | -18.94% |
| 2018 | 5.59 | 15.46% |
| 2017 | 4.84 | 11.08% |
| 2016 | 4.36 | 12.58% |
| 2015 | 3.87 | 51.08% |
| 2014 | 2.56 | 4.01% |
| 2013 | 2.47 | 110.13% |
| 2012 | 1.17 | 65.28% |
| 2011 | 0.71 | -30.21% |
| 2010 | 1.02 | -7.80% |
| 2009 | 1.10 | 24.98% |
| 2008 | 0.88 | -22.93% |
| 2007 | 1.15 | -19.92% |
| 2006 | 1.43 | -69.73% |
| 2005 | 4.73 | -36.01% |
| 2004 | 7.39 | -30.56% |
| 2003 | 10.64 | 52.20% |
| 2002 | 6.99 | 40.54% |
| 2001 | 4.97 | 73.37% |
| 2000 | 2.87 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 3.6116 | 48.05% |
US
|
|
| 2.4596 | 0.82% |
IE
|
|
| 4.7555 | 94.94% |
US
|
|
| 2.513 | 3.01% |
DE
|
|
| 4.9948 | 104.75% |
US
|
Boston Scientific CorporationのP/B比率（PBR）に関する質問
Boston Scientific CorporationのP/B比率（PBR）はどのくらいですか？
2026年11月時点で、Boston Scientific CorporationのP/B比率（PBR）は2.44です。
Boston Scientific Corporationの2025年のP/B比率（PBR）はどのくらいでしたか？
2025年のBoston Scientific CorporationのP/B比率（PBR）は5.83で、2024年は6.04でした。
Boston Scientific CorporationのP/B比率（PBR）は2020年以降どのように推移していますか？
2020年から2025年までのBoston Scientific CorporationのP/B比率（PBR）は、2024年（6.04）が最も高く、2020年（3.32）が最も低くなっています。
Boston Scientific CorporationのP/B比率（PBR）は類似企業と比べてどうですか？
Boston Scientific CorporationのP/B比率（PBR）は2.44で、上に挙げた類似企業5社のすべてを下回っています。これらの企業の中で最も高いのはEdwards Lifesciences Corporationで、4.99です。